Trial Profile

A clinical trial to evaluate ARGX-109

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gerilimzumab (Primary)
Indications Unspecified
Focus Adverse reactions

Most Recent Events

13 Jan 2025 According to Argenx media release, Phase 1 results expected for ARGX-109 in second half of 2025.
07 Mar 2024 New trial record
29 Feb 2024 According to Argenx media release, the company is on track to file investigational new drug (IND) applications by end of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com